-
Today18/04/2025
Utilities
- indicates CPV codes deduced from the text of the procedure
- indicates text translated automatically in your browsing language
Selection of the medicinal product Qarziba (dinutuximab beta) for the period 22.4.-31.12.2025 + option 2026 for the pharmaceutical supply ring of the well-being area of Northern Ostrobothnia Text automatically translated in your browsing language Automatically translated
Direct supply of Qarziba (dinutuximab beta). There is only one dinutuximab beta product on the Finnish market, Qarziba. Qarziba is selected for use in accordance with the SPC: for the treatment of high-risk neuroblastoma in patients aged 12 months and older. Finland currently treats children with high-risk neuroblastoma with an international HR-NBL 1.8 SIOPEN treatment plan, one of which includes Qarziba medication. Text automatically translated in your browsing language Automatically translated
Lapin hyvinvointialue
Keski-Pohjanmaan hyvinvointialue
33600000 - Pharmaceutical products
24000000 - Chemical products CVP code deduced from the text of the procedure AI-generated
Type: cost
Description: Suomen markkinoilla on vain yksi toimittaja, joka voi toteuttaa hankinnan.
Weight (percentage, exact):
This content published on this page is meant purely as an additional service and has no legal effect. The Union's institutions do not assume any liability for its contents. The official versions of the relevant tendering notices are those published in the Supplement of Official Journal of the European Union and available in TED. Those official texts are directly accessible through the links embedded in this page. For more information please see Public Procurement Explainability and Liability notice.